Pradžia EN

Misijos „Vėžys“ partnerystės pasiūlymai

Tematika, kvietimai

Institucija, mokslininkai

Šalis

Papildoma informacija

HORIZON-MISS-2021-CANCER-02-02

 

University of Antwerp and Leuven

An De Groef

An.degroef@uantwerpen.be / an.degroef@kuleuven.be

BE

Participation in coordinating a Work Package focused on the (further) development and validation of a set of quality of life and patient preference measures for cancer patients and survivors. In collaboration with the University Hospitals of Antwerp and Leuven and their regional network, we have access to a large group of cancer patients/survivors in Belgium.

HORIZON-MISS-2021-CANCER-02-01

HORIZON-MISS-2021-CANCER-02-03

Research and Innovation in Health (i3S) of the University of Porto

celsor@i3s.up.pt

PT

We are willing to join a consortium addressing the CANCER MISSION Call topics:

HORIZON-MISS-2021-CANCER-02-01: Develop new methods and technologies for cancer screening and early detection.

HORIZON-MISS-2021-CANCER-02-03: Better understanding of the impact of risk factors and health determinants on the development and progression of cancer

HORIZON-MISS-2021-CANCER-02-01

 

www.bentenbiotech.com

Jorge Wenzel

jorgewenzel@bentenbiotech.com

UY

Benten Biotech (www.bentenbiotech.com) is an SME that develops innovative products and processes in biotechnology, focused on animal and human health. Within our areas of expertise are the discovery, R&D and production for preclinical phases of monodomain recombinant monoclonal antibodies (VHH antibodies, recombinant monodomain antibodies). Within the capabilities of our platform is native or recombinant antigens development, and its standardization for immunoassays or immunotherapies based on monodomain antibodies. At Benten we are continually looking for partners that allow us to enhance joint value propositions, co-develop new products or processes to quickly advance in the development of health solutions. We are particularly interested in participating in innovation clusters with companies from the EU or associated countries, to contribute in phases of discovery, R&D as well as with preclinical candidates in immunodiagnostics and immunotherapies using VHH antibodies. We need partners to perform clinical phases or IVD validation for the products based in VHH antibodies candidates that Benten develops. info@bentenbiotech.com

HORIZON-MISS-2021-CANCER-02-01

HORIZON-MISS-2021-CANCER-02-03

TUBITAK Marmara Research Center Medical Biotechnology Research Group,

Molecular Oncology Team Abdullah.karada@tubitak.gov.tr

TR

Medical Biotechnology Research Group is composed of four teams; molecular oncology, diagnostic, biopharmaceutical, and vaccine teams. The group has great expertise in biomarker development, NGS, LC-MS/MS, hybridoma technology, antibody engineering, biopharmaceuticals, and CAR-T cell therapies.

For HORIZON-MISS-2021-CANCER-02-01: 

We are looking for partners with expertise in development of screening, early diagnosis, monitoring, and therapeutic systems based on molecular profiles and target molecules identified with our previous work.

Printing NGS-based DNA/RNA chips

  • Printing antibody arrays
  • Developing multiplex systems
  • Developing vaccines, biopharmaceuticals, cell therapies, therapeutic small molecules, and/or RNA-therapeutics for identified target molecules

For

HORIZON-MISS-2021-CANCER-02-03:

We are looking for partners with expertise in exosomes, primary cell isolation from cancer cells as well as normal liver, brain, and bone cells. 2D and 3D co-culture systems, NGS, LC-MS/MS, and Bioinformatics is also welcomed!

HORIZON-MISS-2021-CANCER-02-01

University of Siena

Chiara Falciani

chiara.falciani@unisi.it – research.eu@unisi.it
IT

The partner is an expert in three emerging fields: a) HSPGs in cancer, b) tumor-specific peptides and c) cancer related exosomes. Heparan sulfated proteo-glycan HSPG, a family of highly glycosylated, highly sufated proteins. HSPG-related genes are often expressed differently in tumors than in normal tissues. In fact, HSPG bind cytokines and growth factors and eventually influence tumor progression by alterating the tumor microenvironment.

The proponent has long time expertise and knowledge in the field of branched nano-peptides selected against cancer cells. Nano-peptides are long-lived and can be engineered to address their selectivity towards specific targets, can be modified with visible probes and can be immobilized on surfaces, to be used as alternative to antibodies to trap ligands.

The proponent group has already studied endosomes internalization in cancer cell lines, mediated by HSPG. The crucial role of exosomes in cancer is now very well established, but all the benefits that exosomes could bring in cancer detection and management are far from being exploited yet and cutting edge technologies have to be developed to reach the goal.

The group has the expertise to identify a set of differentially expressed protein/glycan/RNA to address the need of faster, earlier, more precise, personalised, accessible and affordable screening and early detection of cancer.

UNISI has state of the art equipped labs with: high throughput peptide synthesizers, HPLC, cell culture facility, multiarray readers, Surface Plasmon Resonance, flow cytometry, confocal microscopy.

HORIZON-MISS-2021-CANCER-02-01

Bar Ilan University (BIU)

lior.lobel@biu.ac.il

IL CONTRIBUTIONS TOWARD CALL TOPIC My team and I bring knowledge and expertise in bacterial genetics and physiology, and immune responses to bacteria and cancer. We are particularly interested in how diet interacts with bacterial metabolic activity, at the protein level, to regulate host metabolism and/or immune responses. We bring a wealth of state-of-the-art molecular biology techiniques spanning genomics (e.g., metagenomics and scrna-seq) and proteomics (tmt-labeled proteome quantification). We also work with in vitro cell cultures and in vivo mouse models. We hope to collaborate with groups studying cell biology, cancer biology, anti-tumor immunity and/or epidimiology.
HORIZON-MISS-2021-CANCER-02-03

Bar Ilan University (BIU)

lior.lobel@biu.ac.il
IL CONTRIBUTIONS TOWARD CALL TOPIC My team and I bring knowledge and expertise in bacterial genetics and physiology, and immune responses to bacteria and cancer. We are particularly interested in how diet interacts with bacterial metabolic activity, at the protein level, to regulate host metabolism and/or immune responses. We bring a wealth of state-of-the-art molecular biology techiniques spanning genomics (e.g., metagenomics and scrna-seq) and proteomics (tmt-labeled proteome quantification). We also work with in vitro cell cultures and in vivo mouse models. We hope to collaborate with groups studying cell biology, cancer biology, anti-tumor immunity and/or epidimiology.
HORIZON-HLTH-2021-DISEASE-04-05

Bar Ilan University (BIU)

lior.lobel@biu.ac.il

IL CONTRIBUTIONS TOWARD CALL TOPIC My team and I bring knowledge and expertise in bacterial genetics and physiology, and immune responses to bacteria and cancer. We are particularly interested in how diet interacts with bacterial metabolic activity, at the protein level, to regulate host metabolism and/or immune responses. We bring a wealth of state-of-the-art molecular biology techiniques spanning genomics (e.g., metagenomics and scrna-seq) and proteomics (tmt-labeled proteome quantification). We also work with in vitro cell cultures and in vivo mouse models. We hope to collaborate with groups studying cell biology, cancer biology, anti-tumor immunity and/or epidimiology. 
HORIZON-MISS-2021-CANCER-02-01

Open University of Israel
Noam Shental, PhD shental@openu.ac.il

IL One avenue of research in the Shental lab is development of combinatorial single-stage group testing applications in biology. In a 2010 paper, we presented a novel, simple, and generic approach for identifying carriers of rare, single-nucleotide polymorphisms (SNPs) in very large cohorts (1). The method, dubbed ComSeq (Figure 1), combines the mathematical field of compressed sensing and next-generation sequencing (NGS) to perform single-stage grouptesting-based screening. In brief, DNA samples are pooled by a liquid handling robot such that each sample participates in several (3-6) pools according to a specific pooling design. The pools undergo sample preparation and are sequenced as if they were regular samples. Sequencing results are then provided to ComSeq which detects all carriers, and predicts whether mutations are homozygous or heterozygous. Hence, after a single round of testing ComSeq provides the same results as would have been achieved by individual testing, yet 10-20 fold more efficiently.